Loading...
Please wait, while we are loading the content...
Similar Documents
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes
| Content Provider | Scilit |
|---|---|
| Author | Zeidan, Amer M. Klink, Andrew J. McGuire, Michael Feinberg, Bruce |
| Copyright Year | 2019 |
| Description | Lenalidomide and hypomethylating agents (HMAs) azacitidine and decitabine are approved for treating myelodysplastic syndromes (MDS), but optimal sequencing is unclear. Adults with MDS were identified from a US payer claims database (Inovalon $MORE^{2}$ Registry) to compare outcomes with lenalidomide followed by HMA (LEN-HMA) or HMA followed by lenalidomide (HMA-LEN). There were 96 patients who received LEN-HMA and 89 who received HMA-LEN. LEN-HMA-treated patients had a longer time to second treatment discontinuation (29.0 vs. 19.0 months, p=.009; adjusted hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.29–0.91, p=.023). LEN-HMA-treated patients had a longer median time to insurance disenrollment (22.4 vs. 16.1 months, p<.001; adjusted HR 0.64, 95% CI: 0.44–0.92, p=.017), used as a proxy for survival. Longer treatment duration and survival with LEN-HMA support first-line use of lenalidomide in MDS in sequence with HMAs. |
| Related Links | https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1551538?needAccess=true |
| Ending Page | 2055 |
| Page Count | 6 |
| Starting Page | 2050 |
| ISSN | 10428194 |
| e-ISSN | 10292403 |
| DOI | 10.1080/10428194.2018.1551538 |
| Journal | Leukemia & Lymphoma |
| Issue Number | 8 |
| Volume Number | 60 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2019-07-03 |
| Access Restriction | Open |
| Subject Keyword | Journal: Leukemia & Lymphoma Hematology Azacitidine Decitabine Lenalidomide Myelodysplastic Syndromes Retrospective |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology Cancer Research Oncology |
